DASATINIB

作品数：30被引量：54H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：杨波何俏军黄常康叶建胜邵雪晶更多>>
相关机构：浙江大学山西医科大学中国科学院大学江苏先声药物研究有限公司更多>>
相关期刊：《World Journal of Gastrointestinal Pathophysiology》《Journal of Biomedical Research》《国外药讯》《中国药物化学杂志》更多>>
相关基金：国家自然科学基金北京市自然科学基金中国博士后科学基金山西省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 主题=NILOTINIBx
共 条 记 录，以下是1-5
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Clinical Effect of Imatinib,Nilotinib,and Dasatinib on Chronic Myeloid Leukemia in Chronic Phase
《Journal of Clinical and Nursing Research》2022年第4期17-21,共5页Yudi Miao 
The study was conducted to explore the effect of imatinib,nilotinib,and dasatinib in the treatment of chronic myeloid leukemia(CML)patients.Around 66 patients with CML in chronic phase were selected,subsequently the p...
关键词：IMATINIB NILOTINIB DASATINIB Chronic myeloid leukemia Chronic phase Clinical effect 
Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
《China Medical Abstracts(Internal Medicine)》2020年第2期111-112,共2页YUAN Ting 
Objective To explore the efficacy and prognosis of nilotinib or dasatinib as second-or third-line treatment in patients with chronic myeloid leukemia(CML)in the chronic phase(CP)and accelerated phase(AP).Methods From ...
关键词：PATIENTS MYELOID LEUKEMIA 
A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma被引量：8
《Journal of Pharmaceutical Analysis》2017年第6期374-380,共7页Jing Zeng Hualin Cai Zhiping Jiang Qing Wang Yan Zhu Ping Xu Xielan Zhao 
A sensitive, rapid, simple and economical ultra-performance liquid chromatography-tandem mass spectrometric method （UPLC-MS/MS） was developed and validated for simultaneous determination of imatinib, dasatinib and n...
关键词：UPLC-MS/MS IMATINIB DASATINIB NILOTINIB POLYMORPHISM 
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase被引量：1
《Frontiers of Medicine》2015年第3期304-311,共8页Lanping Xua Huanling Zhu Jianda Hu Depei Wu Hao Jiang Qian Jiang Xiaojun Huang 
Acknowledgements The Chinese CML alliance provided the data. This work was partly supported by grants from the Collaborative Innovation Center of Hematology in China, the Key Program of the National Natural Science Foundation of China （81230013）, and the Beijing Municipal Science and Technology Commission （Nos. Z121107002812033 and Z121107002612035）.
In the tyrosine kinase inhibitor （TKI） era, imatinib is the first-line therapy for patients with chronic myeloid leukemia （CML） in chronic or accelerated phase. Although second-generation TKIs （TKI2）, including ...
关键词：chronic myeloid leukemia IMATINIB DASATINIB NILOTINIB allogeneic hematopoietic stem cell transplantation 
慢性粒细胞白血病一线治疗药物研究进展被引量：2
《国际输血及血液学杂志》2011年第4期312-315,共4页何丛(综述) 周励(审校) 沈志祥(审校) 
第一代BCR-ABL酪氨酸激酶抑制剂（ tyrosine kinase inhibitors, TKIs）伊马替尼（Imatinib）足慢性粒细胞白血病（chronic myeloid leukemia, CML）慢性期的一线标准治疗。伊马替尼通过直接靶向作用于Bcr—Abl激酶，极大改善了CMI。病...
关键词：慢性粒细胞性白血病(CML) 伊马替尼(Imatinib) 尼洛替尼(Nilotinib) 达沙替尼(Dasatinib) 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部